Moreover, the ABCP regimen may exhibit superior efficacy in a specific EGFR subtype, as the EGFR L858R subtype has been reported to positively influence the efficacy of ICIs in EGFR-sensitizing NSCLC [15,16]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.